medigraphic.com

2020, Number 1

<< Back Next >>

Rev Mex Anest 2020; 43 (1)

Subcutaneous dexmedetomidine. Is it useful in the perioperative of the pediatric patient?

Álvarez‑Betancourt AE, Sánchez‑Hernández E, López‑González BG, Rodríguez‑Moreno ÓA

Language: Spanish
References: 19
Page: 16-22
PDF size: 235.95 Kb.


ABSTRACT

Introduction: Dexmedetomidine is an alpha 2 agonist, several clinical effects has been attributed (antinociceptive, hypnotic-sedative, anesthetic, cardiovascular, ventilatory, renal, endocrine and ocular), varied mechanisms of action, and versatility in its administration pathways. It has been used as adjuvant during the perioperative period providing sedation, anxiolysis, delirium prevention and analgesia. In this study we evaluated exclusively subcutaneous administration as an adjuvant, its implications on pain and postoperative comfort (PO). Material and methods: A prospective, observational, descriptive series of cases was performed. Patients 3-15 years of age, scheduled for low abdominal surgery, both genders, ASA I, II. They were divided into four groups: Group I. placebo, group II, III and IV received dexmedetomidine hydrochloride 1, 1.5 and 2 µg/kg respectively. The placebo or dexmedetomidine hydrochloride was administered subcutaneously in the deltoid region. The sedation, delirium and comfort scale were titrated in the immediate postoperative PO to assess the impact of the dose of dexmedetomidine during the emersion. Subsequently, three evaluations of the hemodynamic parameters (TA, FC, SpO2) were performed, as well as the intensity of the pain, the first one at the end of the surgical procedure, 12 and at 24 hours later. Conclusions: Subcutaneous administration of dexmedetomidine in the pediatric patient is a safe and effective alternative, preserving respiratory function, with adequate sedation, hemodynamic stability, improving analgesia (up to 24 hours) after the surgical event, less agitation and delirium in the postoperative resulting in greater comfort.


REFERENCES

  1. López-González BG, Sánchez-Hernández E, Rodríguez-Moreno OA. Dexmedetomidina por vía Subcutánea como coadyuvante anestésico en el paciente pediátrico después de apendicectomía abierta [Tesis]. Guadalajara, México: Universidad de Guadalajara; 2016. No publicada. En archivo de bibliohemeroteca del Hospital Civil de Guadalajara “Fray Antonio Alcalde”.

  2. Shukry M, Kennedy K. Dexmedetomidine as a total intravenous anesthetic in infants. Paediatr Anaesth. 2007;17:581-583.

  3. Munro HM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Paediatr Anaesth. 2007;17:109-112.

  4. Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol. 2014;15:263-266.

  5. Mato M, Pérez A, Otero J, Torres L. Dexmedetomidina, un fármaco prometedor. Rev Esp Anestesiol Reanim. 2002;49:407-420.

  6. Carrillo-Torres O, Pliego-Sánchez MG, Gallegos-Allier MM, et al. Utilidad de la dexmedetomidina en diversos contextos en la medicina actual. Rev Mex Anestesiol. 2014;37:27-34.

  7. Cortinez LI, Hsu YW, Sum-Ping ST, Young C, Keifer JC, Macleod D, et al. Dexmedetomidine pharmacodynamics: Part II: Crossover comparison of the analgesic effect of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101:1077-1083.

  8. Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, et al. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology. 2006;105:902-910; quiz 1069-1070.

  9. Hogue C, Tlake P, Stein P, Richardson C, Domitrovich P, Sessier D. Autonomic nervous system responses during sedative infusions of dexmedetomidina. Anesthesiology. 2002;97:592-598.

  10. Ramsay M. Bariatric surgery: The role of dexmedetomidine. Critical Care Medicine. 2006;25:51-56.

  11. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman. Las bases farmacológicas de la terapéutica. 11 edición. Μgraw-Hill; 2010. pp. 4-6.

  12. Kivisto KT, Kallio A, Neuvonen PJ. Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine Eur J Clin Pbarmacol. 1994;46:345-349.

  13. Gutiérrez-Vega A, Grandeño-Vega A, Villareal-Careaga J. Dexmedetomidina subcutánea para disminuir los requerimientos de halogenados y narcóticos en anestesia general balanceada, para cirugía de mastectomía. Arch Salud Sin. 2011;5:13-18.

  14. Schanabel A, Reichi SU, Poepping DM, et al. Efficacy and safety of intraoperative dexmedetomidne for acute postoperative pain in children. Paediatr Anaesth. 2013;23:170-179.

  15. Shagufta N, Erum O. Dexmedetomidine in current anaestesia practice: a review. J Clin Diagn Res. 2014;8:GE01-GE04.

  16. Martin JC, Liley DT, Davidson AJ, Sanders RD, Sleigh JW. Multi-channel brain electrical activity in a 5 year old preceding an episode of emergence delirium. ASA Annual congress abstract A951, 2012.

  17. Dahmani S, Delivet H, Hilly J. Emergence delirium in children: an update. Curr Opin Anaesthesiol. 2014;27:309-315.

  18. Ibacache ME, Munoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004;98:60-63.

  19. Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth. 2005;15:762-766.




2020     |     www.medigraphic.com